Skip to main content
NCBI home page
CNS Drug Reviews logoLink to CNS Drug Reviews
. 2006 Jun 7;10(1):1–22. doi: 10.1111/j.1527-3458.2004.tb00001.x

Review of the Pharmacological and Clinical Profile of Rimcazole

Deborah L Gilmore 1, Yun Liu 1, Rae R Matsumoto 1,✉
PMCID: PMC6741722  PMID: 14978511

ABSTRACT

Rimcazole is a carbazole derivative that acts in part as a σ receptor antagonist. Wellcome Research Laboratories introduced this compound during the 1980s when it was hypothesized to be a novel antipsychotic with an improved side effect profile. However, subsequent clinical trials demonstrated that rimcazole lacked efficacy in schizophrenic patients and it is now primarily used as an experimental tool. In addition to its actions as a σ receptor antagonist, rimcazole also has high affinity for dopamine transporters, and in recent years it has served as a lead compound for the development of novel dopamine transporter ligands. Although rimcazole cannot be considered a selective ligand for σ receptors, the recent development of other selective agonists and antagonists for σ receptors have aided in clarifying the involvement of these receptors in the actions of rimcazole. Many of the physiological and behavioral effects of rimcazole can in fact be ascribed to its action as a σ receptor antagonist, although there are exceptions. Rimcazole is likely to have a continued role in elucidating σ receptor function in either in vitro or in vivo systems where σ receptor‐mediated effects can be studied independently of the influence of dopamine and serotonin transporters.

Keywords: Antitussive, Cancer, Convulsion, Depression, Dopamine transporter, Loco‐motor activity, Neuroprotection, Nociception, Pineal, Rimcazole, σ Receptor, Schizophrenia, Ulcer

Full Text

The Full Text of this article is available as a PDF (134.5 KB).

REFERENCES

  • 1. Al‐Nabulsi I, Mach RH, Wang LM, et al. Effect of ploidy, recruitment, environmental factors, and tamoxifen treatment on the expression of σreceptors in proliferating and quiescent tumor cells. Br J Cancer 1999; 81:925–933. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Barg J, Thomas GE, Bem WT, et al. In vitro and in vivo expression of opioid and σ receptors in rat C6 glioma and mouse N18TG2 neuroblastoma cells. J Neurochem 1994; 63:570–574. [DOI] [PubMed] [Google Scholar]
  • 3. Bastianetto S, Perrault G, Sanger DJ. Pharmacological evidence for the involvement of σ sites in DTG‐induced contralateral circling in rats. Neuropharmacology 1995; 34:107–114. [DOI] [PubMed] [Google Scholar]
  • 4. Bastianetto S, Rouquier L, Perrault G, Sanger DJ. DTG‐induced circling behaviour in rats may involve the interaction between σ sites and nigro‐striatal dopaminergic pathways. Neuropharmacology 1995; 34:281–287. [DOI] [PubMed] [Google Scholar]
  • 5. Beart PM, O'Shea RD, Manallack DT. Regulation of σ‐receptors: High‐ and low‐affinity agonist states, GTP shifts, and up‐regulation by rimcazole and 1,3–di(2–tolyl)guanidine. J Neurochem 1989; 53:779–788. [DOI] [PubMed] [Google Scholar]
  • 6. Bem WT, Thomas GE, Mamone JY, et al. Overexpression of σ receptors in nonneural human tumors. Cancer Res 1991; 51:6558–6562. [PubMed] [Google Scholar]
  • 7. Bermack J, Lavoie N, Dryver E, Debonnel G. Effects of σ ligands on NMDA receptor function in the bulbectomy model of depression: A behavioural study in the rat. Int J Neuropsychopharmacol 2002; 5:53–62. [DOI] [PubMed] [Google Scholar]
  • 8. Booth RG, Baldessarini RJ. (+)‐6,7‐benzomorphan σ ligands stimulate dopamine synthesis in rat corpus striatum tissue. Brain Res 1991; 557:349–352. [DOI] [PubMed] [Google Scholar]
  • 9. Borison, RL , Diamond BI, Dren AT. Does σ receptor antagonism predict clinical antipsychotic efficacy Psychopharmacol Bull 1991; 27:103–106. [PubMed] [Google Scholar]
  • 10. Borowicz KK, Wilczynski PM, Kleinrok Z, Czuczwar SJ. Rimcazole, a σ receptor ligand, and the anticonvulsive action of conventional antiepileptic drugs. J Neural Transm 1998; 105:601–612. [DOI] [PubMed] [Google Scholar]
  • 11. Brent PJ. Kappa opioid receptor agonists inhibit σ1 receptor binding in guinea‐pig brain, liver and spleen: Autoradiographical evidence. Brain Res 1996; 725:155–165. [DOI] [PubMed] [Google Scholar]
  • 12. Brent PJ, Herd L, Saunders H, Sim ATR, Dunkley PR. Protein phosphorylation and calcium uptake into rat forebrain synaptosomes: Modulation by the σ ligand, 1,3‐ditolyguanidine. J Neurochem 1997; 68:2201–2211. [DOI] [PubMed] [Google Scholar]
  • 13. Brent PJ, Pang GT. σ Binding site ligands inhibit cell proliferation in mammary and colon carcinoma cell lines and melanoma cells in culture. Eur J Pharmacol 1995; 278:151–160. [DOI] [PubMed] [Google Scholar]
  • 14. Brent PJ, Pang G, Little G, Dosen PJ, Van Helden DF. The σ receptor ligand, reduced haloperidol, induces apoptosis and increases intracellular‐free calcium levels [Ca2+ i in colon and mammary adenocarcinoma cells. Biochem Biophys Res Commun 1996; 219:219–226. [DOI] [PubMed] [Google Scholar]
  • 15. Campbell BG, Scherz MW, Keana JFW, Weber E. σ Receptors regulate contractions of the guinea pig ileum longitudinal muscle/myenteric plexus preparation elicited by both electrical stimulation and exogenous serotonin. J Neurosci 1989; 9:3380–3391. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Cao J, Kulkarni SS, Husbands et al. Dual probes for the dopamine transporter and σ1 receptors: Novel piperazinyl alkyl‐bis(4′‐fluorophenyl)amine analogues as potential cocaine‐abuse therapeutic agents. J Med Chem 2003; 46:2589–2598. [DOI] [PubMed] [Google Scholar]
  • 17. Cao J, Husbands SM, Kopajtic T, Katz JL, Newman AH. [3‐cis‐3,5‐Dimethyl‐(1–piperrazinyl)alkyl]‐bis‐(4′‐fluorophenyl)amine analogues as novel probes for the dopamine transporter. Bioorg Med Chem Lett 2001; 11:3169–3173. [DOI] [PubMed] [Google Scholar]
  • 18. Ceci A, Smith M, French ED. Activation of the A10 mesolimbic system by the σ‐receptor agonist (+)SKF 10,047 can be blocked by rimcazole, a novel putative antipsychotic. Eur J Pharmacol 1988; 154:53–57. [DOI] [PubMed] [Google Scholar]
  • 19. Chouinard G, Annable L. An early phase II clinical trial of BW234U in the treatment of acute schizophrenia in newly admitted patients. Psychopharmacology 1984; 84:282–284. [DOI] [PubMed] [Google Scholar]
  • 20. Church J, Fletcher EJ. Blockade by σ site ligands of high voltage‐activated Cass2+ channels in rat and mouse cultured hippocampal pyramidal neurones. Br J Pharmacol 1995; 116:2801–2810. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. Clissold DB, Pontecorvo MJ, Jones BE, et al. NPC 16377, a potent and selective s‐ligand. II. Behavioral and neuroprotective profile. J Pharmacol Exp Ther 1993; 265:876–886. [PubMed] [Google Scholar]
  • 22. Coccini T, Costa LG, Manzo L, et al. Two subtypes of enteric non‐opioids receptors in guinea‐pig cholinergic motor neurons. Eur J Pharmacol 1991; 198:105–108. [DOI] [PubMed] [Google Scholar]
  • 23. Contreras PC, Bremer ME, Rao TS. GBR‐12909 and fluspirilene potently inhibited binding of [3H](+)3–PPP to σ receptors in rat brain. Life Sci 1990; 47:PL133–PL137. [DOI] [PubMed] [Google Scholar]
  • 24. Crawford KW, Bowen WD. σ2 Receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumor cell lines. Cancer Res 2002; 62:313–322. [PubMed] [Google Scholar]
  • 25. Crawford KW, Coop A, Bowen WD. σ2 Receptors regulate changes in sphingolipid levels in breast tumor cells. Eur J Pharmacol 2002; 443:207–209. [DOI] [PubMed] [Google Scholar]
  • 26. Cryan JF, Markou A, Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 2002; 23:238–245. [DOI] [PubMed] [Google Scholar]
  • 27. Dalvi A, Lucki I. Murine models of depression. Psychopharmacology 1999; 147:14–16. [DOI] [PubMed] [Google Scholar]
  • 28. Davidson J, Miller R, Wingfield M, Zung W, Dren AT. The first clinical study of BW‐234U in schizophrenia. Psychopharmacol Bull 1982; 18:173–176. [PubMed] [Google Scholar]
  • 29. DeCoster MA, Klette KL, Knight ES, Tortella FC. σ Receptor‐mediated neuroprotection against glutamate toxicity in primary rat neuronal cultures. Brain Res 1995; 671:45–53. [DOI] [PubMed] [Google Scholar]
  • 30. DeHaven‐Hudkins DL, Fleissner LC. Competitive interactions at [3H]1,3–di(2–tolyl)guanidine (DTG)‐defined σ recognition sites in guinea pig brain. Life Sci 1992; 50:PL65–PL70. [DOI] [PubMed] [Google Scholar]
  • 31. DeHaven‐Hudkins DL, Fleissner LC, Ford‐Rice FY. Characterization of the binding of [3H](+)‐pentazocine to σ recognition sites in guinea pig brain. Eur J Pharmacol 1992; 227:371–378. [DOI] [PubMed] [Google Scholar]
  • 32. DeHaven‐Hudkins DL, Hildebrand LM, Fleissner LC, Ward SJ. Lack of correlation between σ binding potency and inhibition of contractions in the mouse vas deferens preparation. Eur J Pharmacol 1991; 203:329–335. [DOI] [PubMed] [Google Scholar]
  • 33. Dumont M, Roy D, Lemaire S. Nonexocytotic noradrenaline release from rat cardiac synaptosomal‐mitochondrial fractions. J Cardiovasc Pharmacol 1997; 30:302–308. [DOI] [PubMed] [Google Scholar]
  • 34. Ellis Y, Davies JA. The effects of σ ligands on the release of glutamate from rat striatal slices. Naunyn Schmiedeberg's Arch Pharmacol 1994; 350:143–148. [DOI] [PubMed] [Google Scholar]
  • 35. Everaert H, Flamen P, Franken PR, Verhaeghe W, Bossuyt A. σ‐Receptor imaging by means of I123–IDAB scintigraphy: Clinical application in melanoma and non‐small cell lung cancer. Anticancer Res 1997; 17:1577–1582. [PubMed] [Google Scholar]
  • 36. Farber NB, Kim SH, Dikranian K, Jiang XP, Heinkel C. Receptor mechanisms and circuitry underlying NMDA antagonist neurotoxicity. Mol Psychiatry 2002; 7:32–43. [DOI] [PubMed] [Google Scholar]
  • 37. Ferris RM, Tang FLM, Chang KJ, Russell A. Evidence that the potential antipsychotic agent rimcazole (BW 234U) is a specific, competitive antagonist of σ sites in brain. Life Sci 1986; 38:2329–2337. [DOI] [PubMed] [Google Scholar]
  • 38. Ferris RM, Harfenist M, McKenzie GM, Cooper B, Soroko FE, Mazwell RA. BW 234U, (cis‐9‐[3‐(3,5‐dimethyl‐1‐piperazinyl)propyl]carbazole dihydrochloride): A novel antipsychotic agent. J Pharm Pharmacol 1982; 34:388–390. [DOI] [PubMed] [Google Scholar]
  • 39. Fletcher EJ, Church J, Abdel‐Hamid K, MacDonald JF. Blockade by σ site ligands of N‐methyl‐D‐aspartate‐evoked responses in rat and mouse cultured hippocampal pyramidal neurones. Br J Pharmacol 1995; 116:2791–2800. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40. Georg A, Friedl A. Characterization of specific binding sites for [3H]‐1,3–di‐o‐tolylguanidine (DTG) in the rat glioma cell line C6‐BU‐1. Glia 1992; 6:258–263. [DOI] [PubMed] [Google Scholar]
  • 41. Georg A, Friedl A. Identification and characterization of two σ‐like binding sites in the mouse neuroblastoma σ rat glioma hybrid cell line NG108‐15. J Pharmacol Exp Ther 1991; 259:479–483. [PubMed] [Google Scholar]
  • 42. Goyagi T, Bhardwaj A, Koehler RC, Traystman RJ, Hurn PD, Kirsch JR. Potent σ1 receptor ligand 4‐phenyl‐1‐(4‐phenylbutyl)piperidine provides ischemic neuroprotection without altering dopamine accumulation in vivo in rats. Anesth Analg 2003; 96:532–538. [DOI] [PubMed] [Google Scholar]
  • 43. Goyagi T, Goto S, Bhardwaj A, Dawson VL, Hurn PD, Kirsch JR. Neuroprotective effects of σ1‐receptor ligand 4–phenyl‐1‐(4‐phenylbutyl)piperidine (PPBP) is linked to reduced neuronal nitric oxide production. Stroke 2001; 32:1613–1620. [DOI] [PubMed] [Google Scholar]
  • 44. Gudelsky GA. Biphasic effect of σ receptor ligands on the extracellular concentration of dopamine in the striatum of the rat. J Neural Transm 1999; 106:849–856. [DOI] [PubMed] [Google Scholar]
  • 45. Gudelsky GA. Effects of σ receptor ligands on the extracellular concentration of dopamine in the striatum and prefrontal cortex of the rat. Eur J Pharmacol 1995; 286:223–228. [DOI] [PubMed] [Google Scholar]
  • 46. Hara H, Tanaka K, Harada Y, Sukamoto T. σ Receptor‐mediated effects of a new antiulcer agent, KB‐5492, on experimental gastric mucosal lesions and gastric alkaline secretion in rats. J Pharmacol Exp Ther 1994; 269:799–805. [PubMed] [Google Scholar]
  • 47. Harada Y, Hara H, Sukamoto T. Receptor binding profiles of KB‐5492, a novel anti‐ulcer agent, at σ receptors in guinea‐pig brain. Eur J Pharmacol 1994; 256:321–328. [DOI] [PubMed] [Google Scholar]
  • 48. Harada Y, Hara H, Sukamoto T. Characterization of specific (+)‐[3H]N‐allylnormetazocine and [3H] 1,3‐di(2‐tolyl)guanidine binding sites in porcine gastric fundic mucosa. J Pharmacol Exp Ther 1994; 269:905–910. [PubMed] [Google Scholar]
  • 49. Hayashi T, Kagaya A, Takebayashi M, et al. Modulation by σ ligands to intracellular free Ca++ mobilization by N‐methyl‐D‐aspartate in primary culture of rat frontal cortical neurons. J Pharmacol Exp Ther 1995; 275:207–214. [PubMed] [Google Scholar]
  • 50. Hirotsu I, Koyama M, Honbo N, Ohno T. Pharmacological characteristics of hyperambulation induced by the σ ligand (+)‐3‐PPP in rats. Jpn J Pharmacol 1994; 65:1–7. [DOI] [PubMed] [Google Scholar]
  • 51. Hori T, Abe S, Baba A, Suzuki T, Shiraishi H. Effects of repeated phencyclidine treatment on serotonin transporter in rat brain. Neurosci Lett 2000; 280:53–56. [DOI] [PubMed] [Google Scholar]
  • 52. Husbands SM, Izenwasser S, Kopajtic T, et al. Structure‐activity relationships at the monoamine transporters and σ receptors for a novel series of 9–[3‐(cis‐3,5‐dimethyl‐1‐piperazinyl)propyl]carbazole (rimcazole) analogues. J Med Chem 1999; 42:4446–4455. [DOI] [PubMed] [Google Scholar]
  • 53. Husbands SM, Izenwasser S, Loeloff RJ, et al. Isothiocyanate derivatives of 9‐[3‐(cis‐3,5‐dimethyl‐1‐piperazinyl)propyl]carbazole (rimcazole): Irreversible ligands for the dopamine transporter. J Med Chem 1997; 40:4340–4346. [DOI] [PubMed] [Google Scholar]
  • 54. Itzhak Y. Modulation of the PCP/NMDA receptor complex and σ binding sites by psychostimulants. Neurotoxicol Teratol 1994; 16:363–368. [DOI] [PubMed] [Google Scholar]
  • 55. Izenwasser S, Newman AH, Katz JL. Cocaine and several σ receptor ligands inhibit dopamine uptake in rat caudate‐putamen. Eur J Pharmacol 1993; 243:201–205. [DOI] [PubMed] [Google Scholar]
  • 56. Jansen, KLR , Dragunow M, and Faull, RLM. σ Receptors are highly concentrated in the rat pineal gland. Brain Res 1990; 507:158–160. [DOI] [PubMed] [Google Scholar]
  • 57. John CS, Vilner BJ, Bowen WD. Synthesis and characterization of [125I]‐N‐(N‐benzylpiperidin‐4–yl)‐4–iodobenzamide, a new σ receptor radiopharmaceutical: High‐affinity binding to MCF‐7 breast tumor cells. J Med Chem 1994; 37:1737–1739. [DOI] [PubMed] [Google Scholar]
  • 58. John CS, Gulden ME, Vilner BJ, Bowen WD. Synthesis, in vitro validation and in vivo pharmacokinetics of [125I]N‐[2–(4–iodophenyl)ethyl]‐N‐methyl‐2–(1–piperidinyl)ethylamine: A high‐affinity ligand for imaging σ receptor positive tumors. Nucl Med Biol 1996; 23:761–766. [DOI] [PubMed] [Google Scholar]
  • 59. John CS, Bowen WD, Varma VM, McAfee JG, Moody TW. σ Receptors are expressed in human non‐small cell lung carcinoma. Life Sci 1995; 56:2385–2392. [DOI] [PubMed] [Google Scholar]
  • 60. John CS, Vilner BJ, Geyer BC, Moody T, Bowen WD. Targeting σ receptors‐binding benzamides as in vivo diagnostic and therapeutic agents for human prostate tumors. Cancer Res 1999; 59:4578–4583. [PubMed] [Google Scholar]
  • 61. John CS, Gulden ME, Li J, Bowen WD, McAfee JG, Thakur ML. Synthesis, in vitro binding, and tissue distribution of radioiodinated 2‐[125I]N‐(N‐benzylpiperidin‐4‐yl)‐2–iodo benzamide, 2–[125I]BP: A potential σ receptor marker for human prostate tumors. Nucl Med Biol 1998; 25:189–194. [DOI] [PubMed] [Google Scholar]
  • 62. Kamei J. Role of opioidergic and serotonergic mechanisms in cough and antitussives. Pulm Pharmacol 1996; 9:349–356. [DOI] [PubMed] [Google Scholar]
  • 63. Kamei J, Iwamoto Y, Misawa M, Kasuya Y. Effects of rimcazole, a specific antagonist of σ sites, on the antitussive effects of non‐narcotic antitussive drugs. Eur J Pharmacol 1993; 242:209–211. [DOI] [PubMed] [Google Scholar]
  • 64. Karbon EW, Abreu ME, Erickson RH, et al. NPC 16377, a potent and selective σ‐ligand. I. Receptor binding, neurochemical and neuroendocrine profile. J Pharmacol Exp Ther 1993; 265:866–875. [PubMed] [Google Scholar]
  • 65. Katz JL, Libby TA, Kopajtic T, Husbands SM, Newman AH. Behavioral effects of rimcazole analogues alone and in combination with cocaine. Eur J Pharmacol 2003; 468:109–119. [DOI] [PubMed] [Google Scholar]
  • 66. Kennedy C, Jarvis GE, Henderson G. The σ [corrected] ligand rimcazole antagonizes (+)SKF 10,047, but not (+)3–PPP, in the mouse isolated vas deferens. Eur J Pharmacol 1990; 181:315–318. [DOI] [PubMed] [Google Scholar]
  • 67. Kest B, Mogil JS, Sternberg WF, Pechnick RN, Liebeskind JC. 1,3–Di‐o‐tolylguanidine (DTG) differentially affects acute and tonic formalin pain: Antagonism by rimcazole. Pharmacol Biochem Behav 1995; 52:175–178. [DOI] [PubMed] [Google Scholar]
  • 68. Kest B, Mogil JS, Sternberg WF, Pechnick RN, Liebeskind JC. Antinociception following 1,3‐di‐o‐tolylguanidine, a selective σ receptor ligand. Pharmacol Biochem Behav 1995; 50:587–592. [DOI] [PubMed] [Google Scholar]
  • 69. Kilian M, Frey HH. Central monoamines and convulsive thresholds in mice and rats. Neuropharmacology 1973; 12:681–692. [DOI] [PubMed] [Google Scholar]
  • 70. Kitaichi K, Noda Y, Miyamoto Y, et al. Involvement of the serotonergic neuronal system in phencyclidine induced place aversion in rats. Behav Brain Res 1999; 103:105–111. [DOI] [PubMed] [Google Scholar]
  • 71. Klein M, Musacchio JM. High affinity dextromethorphan binding sites in guinea pig brain. Effect of σ ligands and other agents. J Pharmacol Exp Ther 1989; 251:207–215. [PubMed] [Google Scholar]
  • 72. Kobayashi T, Ikeda K, Togashi S, Itoh N, Kumanishi T. Effects of σ ligands on the nociceptin/orphanin FQ receptor co‐expressed with the G‐protein‐activated K+ channel in Xenopus oocytes. Br J Pharmacol 1997; 120:986–987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73. Kotzer CJ, Hay DWP, Dondio G, Giardina G, Petrillo P, Underwood DC. The antitussive activity of δ‐opioid receptor stimulation in guinea pigs. J Pharmacol Exp Ther 2000; 292:803–809. [PubMed] [Google Scholar]
  • 74. Kume T, Nishikawa H, Taguchi R, et al. Antagonism of NMDA receptors by σ receptor ligands attenuates chemical ischemia‐induced neuronal death in vitro . Eur J Pharmacol 2002; 455:91–100. [DOI] [PubMed] [Google Scholar]
  • 75. Lang A, Soosaar A, Koks S, et al. Pharmacological comparison of antipsychotic drugs and σ‐antagonists in rodents. Pharmacol Toxicol 1994; 75:222–227. [DOI] [PubMed] [Google Scholar]
  • 76. Largent BL, Gundlach AL, Snyder SH. σ Receptors on NCB‐20 hybrid neurotumor cells labeled with (+)[3H]SKF 10,047 and (+)[3H]3–PPP. Eur J Pharmacol 1986; 124:183–187. [DOI] [PubMed] [Google Scholar]
  • 77. Lillrank SM, O'Connor WT, Oja SS, Ungerstedt U. Systemic phencyclidine administration is associated with increased dopamine, GABA, and 5‐HIAA levels in the dorsolateral striatum of conscious rats: An in vivo microdialysis study. J Neural Transm Gen Sect 1994; 95:145–155. [DOI] [PubMed] [Google Scholar]
  • 78. Mach RH, Smith CR, Al‐Nabulsi I, Whirrett BR, Childers SR, Wheeler KT. σ2 Receptors as potential biomarkers of proliferation in breast cancer. Cancer Res 1997; 57:156–161. [PubMed] [Google Scholar]
  • 79. Maj J, Rogoz Z, Skuza G. Influence of 1,3–di‐o‐tolylguanidine and rimcazole, selective σ ligands, on apomorphine and neuroleptic effects. Pol J Pharmacol 1993; 45:327–330. [PubMed] [Google Scholar]
  • 80. Maj J, Rogoz Z, Skuza G, Mazela H. Neuropharmacological profile of EMD 57445, a σ receptor ligand with potential antipsychotic activity. Eur J Pharmacol 1996; 315:235–243. [DOI] [PubMed] [Google Scholar]
  • 81. Marsden CD, Jenner P. The pathophysiology of extrapyramidal side‐effects of neuroleptic drugs. Psychol Med 1980; 10:55–72. [DOI] [PubMed] [Google Scholar]
  • 82. Martin WR, Sloan JW. (1994) Historical perspective: Evolution of the concept of σ receptors In: Itzhak Y, Ed. Sigma Receptors. London : Academic Press, 1994:1–19. [Google Scholar]
  • 83. Martin WR, Eades CG, Thompson JA, Huppler RE, Gilbert PE. The effects of morphine‐ and nalorphinelike drugs in the nondependent and morphine‐dependent chronic spinal dog. J Pharmacol Exp Ther 1976; 197:517–532. [PubMed] [Google Scholar]
  • 84. Massamiri T, Duckles SP. Interactions of σ and phencyclidine receptor ligands with the norepinephrine uptake carrier in both rat brain and rat tail artery. J Pharmacol Exp Ther 1991;256:519–524. [PubMed] [Google Scholar]
  • 85. Massamiri T, Duckles SP. Multiple vascular effects of σ and PCP ligands: Inhibition of amine uptake and contractile responses. J Pharmacol Exp Ther 1990; 253:124–129. [PubMed] [Google Scholar]
  • 86. Matsumoto RR, McCracken KA, Pouw B, Zhang Y, Bowen WD. Involvement of σ receptors in the behavioral effects of cocaine: Evidence from novel ligands and antisense oligodeoxynucleotides. Neuropharmacology 2002; 42:1043–1055. [DOI] [PubMed] [Google Scholar]
  • 87. Matsumoto RR, McCracken KA, Friedman MJ, Pouw B, De Costa BR, Bowen WD. Conformationally restricted analogs of BD1008 and an antisense oligodeoxynucleotide targeting σ1 receptors produce anti‐cocaine effects in mice. Eur J Pharmacol 2001; 419:163–174. [DOI] [PubMed] [Google Scholar]
  • 88. Matsumoto RR, McCracken KA, Pouw B, et al. N‐alkyl substituted analogs of the σ receptor ligand BD1008 and traditional σ receptor ligands affect cocaine‐induced convulsions and lethality in mice. Eur J Pharmacol 2001; 411:261–273. [DOI] [PubMed] [Google Scholar]
  • 89. Matsumoto RR, Hewett KL, Pouw B, et al. Rimcazole analogs attenuate the convulsive effects of cocaine: Correlation with binding to σ receptors rather than dopamine transporters. Neuropharmacology 2001; 41:878–886. [DOI] [PubMed] [Google Scholar]
  • 90. Matsuno K, Kobayashi T, Mita S. Involvement of ó‐receptors in the increase in contraction of mouse vas deferens induced by exogenous ATP. J Pharm Pharmacol 1996; 48:96–99. [DOI] [PubMed] [Google Scholar]
  • 91. Matsuno K, Senda T, Mita S. Correlation between potentiation of neurogenic twitch contraction and benzomorphan σ receptor binding potency in the mouse vas deferens. Eur J Pharmacol 1993; 231:451–457. [DOI] [PubMed] [Google Scholar]
  • 92. Matsuno K, Kobayashi K, Tanaka MK, Mita S. σ1 Receptor subtype is involved in the relief of behavioral despair in the mouse forced swim test. Eur J Pharmacol 1996; 312:267–271. [DOI] [PubMed] [Google Scholar]
  • 93. Maurice T, Martin‐Fardon R, Romieu P, Matsumoto RR. σ1 Receptor antagonists represent a new strategy against cocaine addiction and toxicity. Neurosci Biobehav Rev 2002; 26:499–527. [DOI] [PubMed] [Google Scholar]
  • 94. McCracken KA, Bowen WD, de Costa BR, Matsumoto RR. Two novel σ receptor ligands, BD1047 and LR172, attenuate cocaine‐induced toxicity and locomotor activity. Eur J Pharmacol 1999; 370:225–232. [DOI] [PubMed] [Google Scholar]
  • 95. Menkel M, Terry P, Pontecorvo M, Katz JL, Witkin JM. Selective σ ligands block stimulant effects of cocaine. Eur J Pharmacol 1991; 201:251–252. [DOI] [PubMed] [Google Scholar]
  • 96. Monassier L, Bousquet P. σ Receptors: From discovery to highlights of their implications in the cardiovascular system. Fundam Clin Pharmacol 2002; 16:1–8. [DOI] [PubMed] [Google Scholar]
  • 97. Monnet FP, Debonnel G, de Montigny C. In vivo electrophysiological evidence for a selective modulation of N‐methyl‐D‐aspartate‐induced neuronal activation in rat CA3 dorsal hippocampus by σ ligands. J Pharmacol Exp Ther 1992; 261:123–130. [PubMed] [Google Scholar]
  • 98. Monnet FP, Debonnel G, Junien JL, De Montigny C. N‐methyl‐D‐aspartate‐induced neuronal activation is selectively modulated by σ receptors. Eur J Pharmacol 1990; 179:441–445. [DOI] [PubMed] [Google Scholar]
  • 99. Moody TW, Leyton J, John C. σ Ligands inhibit the growth of small cell lung cancer cells. Life Sci 2000; 66:1979–1986. [DOI] [PubMed] [Google Scholar]
  • 100. Morimoto Y, Shimohara K, Oshima S, Sukamoto T. Effects of the new anti‐ulcer agent KB‐5492 on experimental gastric mucosal lesions and gastric mucosal defensive factors, as compared to those of teprenone and cimetidine. Jpn J Pharmacol 1991; 57:495–505. [DOI] [PubMed] [Google Scholar]
  • 101. Nakao S, Miyamoto E, Masuzawa M, Kambara T, Shingu K. Ketamine‐induced c‐Fos expression in the mouse posterior cingulated and retrosplenial cortices is mediated not only via NMDA receptors but also via σ receptors. Brain Res 2002; 926:191–196. [DOI] [PubMed] [Google Scholar]
  • 102. Narita N, Hashimoto K, Tomitaka S, Minabe K. Interactions of selective serotonin reuptake inhibitors with subtypes of ó receptors in rat brain. Eur J Pharmacol 1996; 307:117–119. [DOI] [PubMed] [Google Scholar]
  • 103. Newman AH, Kulkarni S. Probes for the dopamine transporter: New leads toward a cocaine‐abuse therapeutic‐a focus on analogues of benztropine and rimcazole. Med Res Rev 2002; 22:429–464. [DOI] [PubMed] [Google Scholar]
  • 104. Nishikawa H, Hashino A, Kume T, Katsuki H, Kaneko S, Akaike A. Involvement of direct inhibition of NMDA receptors in the effects of σ‐receptor ligands on glutamate neurotoxicity in vitro. Eur J Pharmacol 2000; 404:41–48. [DOI] [PubMed] [Google Scholar]
  • 105. Noda Y, Nabeshima T. Neuronal mechanisms of phencyclidine‐induced place aversion and preference in the conditioned place preference task. Meth Find Exp Clin Pharmacol 1998; 20:607–611. [DOI] [PubMed] [Google Scholar]
  • 106. Nuwayhid SJ, Werling LL. σ1 Receptor agonist‐mediated regulation of N‐methyl‐D‐aspartate‐stimulated [3H]dopamine release is dependent upon protein kinase C. J Pharmacol Exp Ther 2003; 304:364–369. [DOI] [PubMed] [Google Scholar]
  • 107. O'Dell, LE , George, FR , Ritz, MC . Antidepressant drugs appear to enhance cocaine‐induced toxicity. Exp Clin Psychopharmacol 2000; 8:133–141. [DOI] [PubMed] [Google Scholar]
  • 108. Ogawa S, Okuyama S, Araki H, Otomo S. Effect of NE‐100, a novel ó receptor ligand, on phencyclidine induced cognitive dysfunction. Eur J Pharmacol 1994; 263:9–15. [DOI] [PubMed] [Google Scholar]
  • 109. Ogawa S, Okuyama S, Tsuchida K, Araki H, Otomo S. The σ‐selective ligand NE‐100 attenuates the effect of phencyclidine in a rat diving model. Gen Pharmacol 1995; 26:177–182. [DOI] [PubMed] [Google Scholar]
  • 110. Panocka I, Perfumi M, Angeletti S, Ciccocioppo R, Massi M. Effects of Hypericum perforatum extract on ethanol intake, and on behavioral despair: A search for the neurochemical systems involved. Pharmacol Biochem Behav 2000; 66:105–111. [DOI] [PubMed] [Google Scholar]
  • 111. Pascaud X, Defaux JP, Roze C, Junien JL. Effect of selective σ ligands on duodenal alkaline secretion in the rat. J Pharmacol Exp Ther 1990; 255:1354–1359. [PubMed] [Google Scholar]
  • 112. Pascaud XB, Chovet M, Soulard P, Chevalier E, Roze C, Junien JL. Effects of a new σ ligand, JO 1784, on cysteamine ulcers and duodenal alkaline secretion in rats. Gastroenterology 1993; 104:427–434. [DOI] [PubMed] [Google Scholar]
  • 113. Piontek JA, Wang RY. Acute and subchronic effects of rimcazole (BW 234U), a potential antipsychotic drug, on A9 and A10 dopamine neurons in the rat. Life Sci 1986; 39:651–658. [DOI] [PubMed] [Google Scholar]
  • 114. Quattrone A, Samanin R. Decreased anticonvulsant activity of carbamazepine in 6‐hydroxydopamine treated rats. Eur J Pharmacol 1977; 41:333–336. [DOI] [PubMed] [Google Scholar]
  • 115. Quirion R, Bowen WD, Itzhak Y, et al. A proposal for the classification of σ binding sites. Trends Pharmacol Sci 1992; 13:85–86. [DOI] [PubMed] [Google Scholar]
  • 116. Quirion R, Chicheportiche R, Contreras PC, et al. Classification and nomenclature of phencyclidine and σ receptor sites. Trends Neurosci 1987; 10:444–446. [Google Scholar]
  • 117. Raffa RB. Screen of receptor and uptake‐site activity of hypericin component of St. John's wort reveals σ receptor binding. Life Sci 1998; 62:PL265–PL270. [DOI] [PubMed] [Google Scholar]
  • 118. Ramamoorthy JD, Ramamoorthy S, Mahesh VB, Leibach FH, Ganapahty V. Cocaine‐sensitive σ‐receptor and its interaction with steroid hormones in the human placenta syncytiotrophoblast and in choriocarcinoma cells. Endocrinology 1995; 136:924–932. [DOI] [PubMed] [Google Scholar]
  • 119. Rao TS, Mick SJ, Cler JA, et al. Effects of σ ligands on mouse cerebellar cyclic guanosine monophosphate (cGMP) levels in vivo: Further evidence for a functional modulation of N‐methyl‐D‐aspartate (NMDA) receptor complex‐mediated events by σ ligands. Brain Res 1991; 561:43–50. [DOI] [PubMed] [Google Scholar]
  • 120. Rogers C, Lemaire S. Characterization of [3H]desmethylimipramine binding in bovine adrenal medulla: Interactions with σ‐ and (or) phencyclidine‐receptor ligands. Can J Physiol Pharmacol 1992; 70:1508–1514. [DOI] [PubMed] [Google Scholar]
  • 121. Roman F, Pascaud X, Chomette G, Bueno L, Junien JL. Autoradiographic localization of σ opioid receptors in the gastrointestinal tract of the guinea pig. Gastroenterology 1989; 97:76–82. [DOI] [PubMed] [Google Scholar]
  • 122. Roth BL, Craigo SC, Choudhary MS, et al. Binding of typical and atypical antipsychotic agents to 5–hydroxytryptamine‐6 and 5‐hydroxytryptamine‐7 receptors. J Pharmacol Exp Ther 1994; 268:1403–1410. [PubMed] [Google Scholar]
  • 123. Ryan‐Moro J, Chien CC, Standifer KM, Pasternak GW. Sigma binding in a human neuroblastoma cell line. NeurochemRes 1996; 21:1309–1314. [DOI] [PubMed] [Google Scholar]
  • 124. Saller CF, Salama AI. 3‐Methoxytyramine accumulation: Effects of typical neuroleptics and various atypical compounds. Naunyn Schmiedeberg's Arch Pharmacol 1986; 334:125–132. [DOI] [PubMed] [Google Scholar]
  • 125. Seeman P. Tardive dyskinesia, dopamine receptors, and neuroleptic damage to cell membranes. J Clin Psychopharmacol 1988; 8:3S–S. [DOI] [PubMed] [Google Scholar]
  • 126. Sharp FR, Butman M, Wang S, et al. Haloperidol prevents induction of the hsp70 heat shock gene in neurons injured by phencyclidine (PCP), MK801, and ketamine. J Neurosci Res 1992; 33:605–616. [DOI] [PubMed] [Google Scholar]
  • 127. Sharp, JW . Phencyclidine (PCP) acts at σ sites to induce c‐fos gene expression. Brain Res 1997; 758:51–58. [DOI] [PubMed] [Google Scholar]
  • 128. Sharp, JW , Williams DS. Effects of σ ligand on the ability of rimcazole to inhibit PCP hsp70 induction. Brain Res Bull 1996; 39:359–366. [DOI] [PubMed] [Google Scholar]
  • 129. Shibata S, Yamamoto Y, Watanabe S. A role of ó receptors on hypoxia/hypoglycemia‐induced decrease in CA1 presynaptic fiber spikes in rat hippocampal slices. Brain Res 1995; 670:337–341. [DOI] [PubMed] [Google Scholar]
  • 130. Shimohara K, Niida H, Okabe S. Effects of KB‐5492, 1‐(3,4,5‐trimethoxybenzyl)‐4‐((4‐methoxyphenyl)oxycarbonylmethyl)piperazine monofumarate monohydrate, on gastric lesions and gastric secretion in rats. Jpn J Pharmacol 1990; 53:275–279. [DOI] [PubMed] [Google Scholar]
  • 131. Simony‐Lafontaine J, Esslimani M, Bribes E, et al. Immunocytochemical assessment of σ1 receptor and human sterol isomerase in breast cancer and their relationship with a series of prognostic factors. Br J Cancer 2000; 82:1958–1966. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 132. Skuza G. Effect of σ ligands on the cocaine‐induced convulsions in mice. Pol J Pharmacol 1999; 51:477–483. [PubMed] [Google Scholar]
  • 133. Skuza G, Rogoz A. A potential antidepressant activity of SA4503, a selective σ receptor agonist. Behav Pharmacol 2002; 13:537–543. [DOI] [PubMed] [Google Scholar]
  • 134. Skuza G, Rogoz Z. Effect of 1,3‐di‐o‐tolylguanidine (DTG), rimcazole and EMD 57445, the σ receptor ligands, in the forced swimming test. Pol J Pharmacol 1997; 49:329–335. [PubMed] [Google Scholar]
  • 135. Skuza G, Kolasiewicz W, Dziedzicka‐Wasylewska M, Margas W. Effect of local intracerebral administration of EMA 57445, a selective σ receptor ligand, on the locomotor activity of the rat. Pol J Pharmacol 1998; 50:399–406. [PubMed] [Google Scholar]
  • 136. Steardo L, Monteleone P, D'Istria M, Serino I, Maj M, Cuomo V. σ receptor modulation of noradrenergicstimulated pineal melatonin biosynthesis in rats. J Neurochem 1996; 67:287–293. [DOI] [PubMed] [Google Scholar]
  • 137. Steardo L, Monteleone P, D'Istria M, Serino I, Maj M, Cuomo V. (+)‐N‐allylnormetazocine enhances N‐acetyltransferase activity and melatonin synthesis: Preliminary evidence for a functional role of σ receptors in the rat pineal gland. J Pharmacol Exp Ther 1995; 275:845–849. [PubMed] [Google Scholar]
  • 138. Steinfels GF, Tam SW, Cook L. Electrophysiological effects of selective σ‐receptor agonists, antagonists, and the selective phencyclidine receptor agonist MK‐801 on midbrain dopamine neurons. Neuropsychopharmacology 1989; 2:201–208. [DOI] [PubMed] [Google Scholar]
  • 139. Su TP, Schell SE, Ford‐Rice FY, London ED. Correlation of inhibitory potencies of putative antagonists for σ receptors in brain and spleen. Eur J Pharmacol 1988; 148:467–470. [DOI] [PubMed] [Google Scholar]
  • 140. Szallasi A. Autoradiographic visualization and pharmacological characterization of vanilloid (capsaicin) receptors in several species, including man. Acta Physiol Scand Suppl 1995; 629:1–68. [PubMed] [Google Scholar]
  • 141. Szallasi A, Nilsson S, Blumberg PM, Hokfelt T, Lundberg JM. Binding of neuroleptic drugs (trifluoperazine and rimcazole) to vanilloid receptors in porcine dorsal horn. Eur J Pharmacol 1996; 298:321–327. [DOI] [PubMed] [Google Scholar]
  • 142. Takahashi S, Miwa T, Horikomi K. Involvement of σ1 receptors in methamphetamine‐induced behavioral sensitization in rats. Neurosci Lett 2000; 289:21–24. [DOI] [PubMed] [Google Scholar]
  • 143. Terleckyj I, Sonsalla PK. The σ receptor ligand (+/‐)‐BMY 14802 prevents methamphetamine‐induced dopaminergic neurotoxicity via interactions at dopamine receptors. J Pharmacol Exp Ther 1994; 269:44–50. [PubMed] [Google Scholar]
  • 144. Thomas GE, Szucs M, Mamone JY, et al. Sigma and opioid receptors in human brain tumors. Life Sci 1990; 46:1279–1286. [DOI] [PubMed] [Google Scholar]
  • 145. Thompson TL, Bridges S, Miller C. Modulation of dopamine uptake in rat nucleus accumbens: Effect of specific dopamine receptor antagonists and σ ligands. Neurosci Lett 2001; 312:169–172. [DOI] [PubMed] [Google Scholar]
  • 146. Ujike H, Kanzaki A, Okumura K, Akiyama K, Otsuki S. Sigma antagonist BMY 14802 prevents methamphetamine‐induced sensitization. Life Sci 1992; 50:PL129–PL134. [DOI] [PubMed] [Google Scholar]
  • 147. Ujike H, Okumura K, Zushi Y, Akiyama K, Otsuki S. Persistent supersensitivity of σ receptors develops during repeated methamphetamine treatment. Eur J Pharmacol 1992; 211:323–328. [DOI] [PubMed] [Google Scholar]
  • 148. Ujike H, Kuroda S, Otsuki S. σ receptor antagonists block the development of sensitization to cocaine. Eur J Pharmacol 1996; 296:123–128. [DOI] [PubMed] [Google Scholar]
  • 149. Urani A, Roman FJ, Phan VL, Su TP, Maurice T. The antidepressant‐like effect induced by σ1‐receptor agonists and neuroactive steroids in mice submitted to the forced swimming test. J Pharmacol Exp Ther 2001; 298:1269–1279. [PubMed] [Google Scholar]
  • 150. Valchar M, Hanbauer I. Comparison of [3H]WIN 35,428 binding, a marker for dopamine transporter, in embryonic mesencephalic neuronal cultures with striatal membranes of adult rats. J Neurochem 1993; 60:469–476. [DOI] [PubMed] [Google Scholar]
  • 151. Vaupel DB, Su TP. Guinea‐pig vas deferens preparation may contain both σ receptors and phencyclidine receptors. Eur J Pharmacol 1987; 139:125–128. [DOI] [PubMed] [Google Scholar]
  • 152. Vilner BJ, de Costa BR, Bowen WD. Cytotoxic effects of σ ligands: σ Receptor‐mediated alterations in cellular morphology and viability. J Neurosci 1995; 15:117–134. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 153. Vilner BJ, John CS, Bowen WD. σ1 and σ2 receptors are expressed in a wide variety of human and rodent tumor cell lines. Cancer Res 1995; 55:408–413. [PubMed] [Google Scholar]
  • 154. Walker JM, Bowen WD, Walker FO, Matsumoto RR, De Costa B, Rice KC. σ Receptors: Biology and function. Pharmacol Rev 1990; 42:355–402. [PubMed] [Google Scholar]
  • 155. Wettstein JG, Roman FJ, Rocher MN, Junien JL. Effects of σ receptor ligands on schedule‐controlled behavior of rats: Relation to σ and PCP receptor binding affinity. Psychopharmacology 1991; 104:157–163. [DOI] [PubMed] [Google Scholar]
  • 156. Wheeler KT, Wang LM, Wallen CA, et al. σ2 Receptors as a biomarker of proliferation in solid tumours. Br J Cancer 2000; 82:1223–1232. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 157. Witkin JM, Terry P, Menkel M, et al. Effects of the selective σ receptor ligand, 6‐[6‐(4‐hydroxypiperidinyl)hexyloxy]‐3–methylflavone (NPC 16377), on behavioral and toxic effects of cocaine. J Pharmacol Exp Ther. 1993; 266:473–482. [PubMed] [Google Scholar]
  • 158. Yang ZW, Paleos GA, Byrd JC. Expression of (+)‐3‐PPP binding sites in the PC12 pheochromocytoma cell line. Eur J Pharmacol 1989; 164:607–610. [DOI] [PubMed] [Google Scholar]
  • 159. Zamora PO, Moody TW, John CS. Increased binding to σ sites of N‐[1′(2‐piperidinyl)ethyl)‐4–[I‐125]‐iodobenzamide (I‐125‐PAB) with onset of tumor cell proliferation. Life Sci 1998; 63:1611–1618. [DOI] [PubMed] [Google Scholar]

Articles from CNS Drug Reviews are provided here courtesy of Wiley

RESOURCES